Sign in

COCP on Nasdaq

Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is an American pharmaceutical preparations company based in Bothell.2 Its shares trade on Nasdaq under the symbol COCP.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Oramed Pharmaceuticals, Sagimet Biosciences Inc. or Magenta Therapeutics, or pick any stock.

  • TickerCOCP on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersBothell, United States2
  • Incorporated inDE3
  • Business address19805 N. Creek Parkway, Bothell, Wa 980113
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300QCJ6RBUJKI7S662
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 56448302

See how the biggest companies compare on our leaderboards

(including SARS-CoV-2 & MERS-CoV), respiratory virus infections and hepatitis C virus (“HCV”) infections.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-476.0%Operating margin5
-479.0%Net margin5
-69.3%Revenue growth, 20205
-18.4%Return on equity6
-$10.1MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2020

  • Research and development100¢$6.0M
  • Interest0¢$8.0K

Out of $2.0M in revenue.5 The company lost money this year.

Financial statements

Revenue75$2.0M in 2020−69% since 2019
0$2.0M$4.0M$6.0M$8.0M2019: $6.6M$6.6M20192020: $2.0M$2.0M2020−69%
Operating income75-$9.6M in 2020−80% since 2019
-$60.0M-$40.0M-$20.0M02019: -$48.4M-$48.4M20192020: -$9.6M-$9.6M2020−80%
Net income75-$9.6M in 2020−80% since 2019
-$60.0M-$40.0M-$20.0M02019: -$48.2M-$48.2M20192020: -$9.6M-$9.6M2020−80%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development$5.1M$12.5M
General and administrative$4.0M$5.3M
Total operating expenses$9.0M$17.9M
Loss from operations-$9.0M-$17.9M
Interest income, net$134.0K$537.0K
Foreign exchange gain (loss)$54.0K-$163.0K
Total other income, net$188.0K$374.0K
Net loss-$8.8M-$17.5M
Net loss per common share, basic-$0.78-$1.72
Net loss per common share, diluted-$0.78-$1.72
Weighted average number of common shares outstanding, basic11.3M shares10.2M shares
Weighted average number of common shares outstanding, diluted11.3M shares10.2M shares

Compare Cocrystal Pharma, Inc. with another company

Corporate structure

Cocrystal Pharma, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Cocrystal Pharma, Inc.

  • Cocrystal Pharma, Inc. Bothell, Washington, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Cocrystal Pharma, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.1M10 Dec 31, 2025$2.1M10 Dec 31, 2024+0.6%
Accumulated depreciation$2.0M10 Dec 31, 2025$1.9M10 Dec 31, 2024+3.7%
Property and equipment, net$93.0K10 Dec 31, 2025$153.0K10 Dec 31, 2024−39.2%
Operating-lease assets (leased space)$1.4M10 Dec 31, 2025$1.7M10 Dec 31, 2024−17.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$7.0M10 Dec 31, 2025$9.9M10 Dec 31, 2024−28.8%

Properties, in its own words

We have operating facilities in Bothell, Washington and Miami, Florida, as well as an administrative facility in Melbourne, Australia.

We lease approximately 15,400 square feet of office and laboratory space in Bothell, Washington under two operating lease agreements expiring in January 2029 and January 2031, respectively.

The rest of Item 2

We also renewed the existing lease office space in Miami, Florida under a lease that expires in September 2027.

The Company believes that its properties are suitable for their intended purposes and have capacities adequate for current and projected needs related to the Company’s programs.

Item 2 of the 10-K filed Mar 31, 2026.4

Leadership

Who has led Cocrystal Pharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Gary Wilcox2014–2020
  2. Jeffrey A. Meckler2015–2016
  3. James Sapirstein2026–now

Chief financial officer

  1. Gerald A. McGuire2014–2015
  2. Curtis Dale2015
201520202025
Board members and other officers (14)

Former names

  • BIOZONE PHARMACEUTICALS, INC.Mar 31, 2011 to Mar 25, 20143
  • International Surf Resorts, Inc.Sep 20, 2007 to Mar 4, 20113

Timeline

  1. Sep 9, 20268-K Regulation FD disclosure29
  2. Aug 18, 20268-K Executive or director change30
  3. Aug 17, 20268-K Regulation FD disclosure31
  4. Aug 3, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure32
  5. Jul 17, 20268-K Shareholder vote33
  6. Jun 9, 20268-K Executive or director change34
  7. Jun 3, 2026New chief executive James Sapirstein becomes CEO11
  8. Jun 3, 20268-K Regulation FD disclosure35
  9. May 26, 20268-K Regulation FD disclosure36
  10. Apr 30, 20268-K Regulation FD disclosure37
  11. Apr 2, 20268-K Regulation FD disclosure38
  12. Mar 31, 20268-K Results of operations39
  13. Mar 13, 20268-K Executive or director change40
  14. Oct 2, 2015New chief executive Jeffrey A. Meckler becomes CEO12
  15. Mar 17, 2014New chief executive Gary Wilcox becomes CEO13

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.19) a share, on Nov 14, 2025.41

When it reported results

  1. Mar 31, 2026Reported quarterly or annual results39
  2. Nov 14, 2025Reported quarterly or annual results42
  3. Aug 14, 2025Reported quarterly or annual results43
  4. May 15, 2025Reported quarterly or annual results44
  5. Mar 31, 2025Reported quarterly or annual results45
  6. Nov 13, 2024Reported quarterly or annual results46
  7. Aug 14, 2024Reported quarterly or annual results47
  8. May 13, 2024Reported quarterly or annual results48

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

191 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 81 major events, 49 insider forms, 10 large holders, 30 other. The latest 20:

  1. Sep 9, 20268-K EDGAR
  2. Aug 21, 20263 EDGAR
  3. Aug 18, 20268-K EDGAR
  4. Aug 17, 20268-K EDGAR
  5. Aug 13, 202610-Q EDGAR
  6. Aug 7, 2026SCHEDULE 13D/A EDGAR
  7. Aug 7, 2026SCHEDULE 13D EDGAR
  8. Aug 6, 20264 EDGAR
  9. Aug 5, 20264 EDGAR
  10. Aug 3, 20268-K EDGAR
  11. Jul 17, 20268-K EDGAR
  12. Jun 9, 20268-K EDGAR
  13. Jun 3, 20264 EDGAR
  14. Jun 3, 20263 EDGAR
  15. Jun 3, 20268-K EDGAR
  16. May 27, 2026DEFA14A EDGAR
  17. May 27, 2026DEF 14A EDGAR
  18. May 26, 20268-K EDGAR
  19. May 15, 202610-Q EDGAR
  20. May 1, 2026EFFECT EDGAR

The 191 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

11 open-market trades by officers, directors and large owners since October 2021: 11 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 5, 2026FROST PHILLIP MD ET ALDirectorBuy10,000$0.98$9.8KForm 4
Aug 3, 2026FROST PHILLIP MD ET ALDirectorBuy75,000$0.94$70.5KForm 4
Feb 24, 2026FROST PHILLIP MD ET ALDirectorBuy20,000$1.00$20.0KForm 4
Feb 6, 2026FROST PHILLIP MD ET ALDirectorBuy50,000$0.95$47.5KForm 4
Dec 31, 2025FROST PHILLIP MD ET ALDirectorBuy50,000$0.95$47.5KForm 4
Dec 30, 2025FROST PHILLIP MD ET ALDirectorBuy20,000$0.97$19.4KForm 4
Dec 26, 2025FROST PHILLIP MD ET ALDirectorBuy40,000$0.97$38.8KForm 4
Dec 24, 2025FROST PHILLIP MD ET ALDirectorBuy25,000$0.97$24.2KForm 4
Nov 26, 2025FROST PHILLIP MD ET ALDirectorBuy4,000$0.99$4.0KForm 4
Nov 25, 2025FROST PHILLIP MD ET ALDirectorBuy20,000$0.94$18.8KForm 4
Apr 4, 2023FROST PHILLIP MD ET ALDirectorBuy1,015,229$1.97$2.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025James Martin59$265.0K54
2025Sam Lee66$248.7K54
2024Co-Chief Executive Officer and Chief Financial Officer$410.5K$680.9K54
2024Co-Chief Executive Officer and President$410.5K$680.9K54

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 28. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC358,228$376.1K0.0%+118,257
Renaissance Technologies LLC179,628$188.6K0.0%+55,700
Two Sigma Investments, LP175,379$184.1K0.0%New
Geode Capital Management, LLC76,208$80.0K0.0%−14,023
BlackRock, Inc.73,746$77.4K0.0%No change
Citadel Advisors LLC45,118$47.4K0.0%New
Neuberger Berman Group LLC31,886$33.5K0.0%No change
XTX Topco Ltd29,342$30.8K0.0%−6,689
Jane Street Group, LLC25,761$27.0K0.0%+13,050
Vanguard Fiduciary Trust Co24,016$25.2K0.0%No change
State Street Corp20,543$21.6K0.0%No change
Parallel Advisors, LLC12,569$13.2K0.0%No change
Northern Trust Corp11,921$12.5K0.0%No change
Ground Swell Capital, LLC10,752$11.3K0.0%New
Wells Fargo & Company/mn6,257$6.6K0.0%−782
UBS Group AG4,133$4.3K0.0%−511
Tower Research Capital LLC (TRC)3,984$4.2K0.0%−264
Morgan Stanley871$9150.0%−77
Northwestern Mutual Wealth Management Co817$8580.0%No change
Clean Yield Group418$4390.0%No change
Nvwm, LLC84$880.0%No change
Barclays PLC42$440.0%New
SBI Securities Co., Ltd.33$350.0%No change
Allied Private Wealth LLC32$310.0%New
Hrt Financial LP20,336$210.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Cocrystal Pharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCocrystal Pharma, Inc.1
  • CIK0001412486
  • Employer ID (EIN)35-25282154
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address19805 N. Creek Parkway, Bothell, WA 980111
  • Phone(786) 459-18311
  • Shares outstanding19,263,200 as of Aug 13, 20269
  • Public float$11.6M as of Jun 30, 20254
  • AuditorWeinberg & Company, P.A, Los Angeles, California PCAOB ID 572; it also attests to the company’s internal control over financial reporting4
  • On EDGAR sinceSep 20, 20071
  • Filings672 in all: 8-K (219), 4 (117), 10-Q (56), UPLOAD (26), CORRESP (24), 3 (22), 10-K (18), D (17)1
    All 46 form types

    424B5 (16), SC 13G/A (14), DEF 14A (12), 8-K/A (10), SC 13G (10), DEFA14A (9), EFFECT (9), PRE 14A (8), S-1/A (8), 10-K/A (7), NT 10-K (7), SC 13D/A (7), 10-Q/A (6), NT 10-Q (6), S-3 (6), S-3/A (4), SC 13D (4), 424B3 (3), CT ORDER (3), SCHEDULE 13D/A (3), 144 (2), S-1 (2), S-8 (2), 10KSB (1), 10QSB (1), 4/A (1), 424B7 (1), 5 (1), 8-A12B (1), 8-A12G (1), CERT (1), DEF 14C (1), NT 10-Q/A (1), POS AM (1), PRE 14C (1), RW (1), SB-2 (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) May 27, 2026
    Latest 8-K (8-K) Sep 9, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareCOCPNasdaq

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Cocrystal Pharma, Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 53 risks under these headings, as written.4

  • RISK RELATED TO OUR FINANCIAL CONDITION
  • Because there is substantial doubt as to the Company’s ability to continue as a going concern, we may not be successful and our ability to continue our operations is in doubt unless we can access sufficient working capital within the timeframe needed.
  • RISKS RELATED TO OUR BUSINESS
  • We have never generated revenue from product sales, and all of our product candidates are currently in the preclinical and early clinical stage, and we may continue to incur significant losses for the foreseeable future and never generate revenue from product sales.
  • We had an accumulated deficit of $342.2 million from inception through December 31, 2025 and expect to continue losing money in the future. We may never achieve income from operations or have positive cash flow from operations.
  • Because we have yet to generate any revenue from product sales on which to evaluate our potential for future success and to determine if we will be able to execute our business plan, it is difficult to evaluate our prospects and the likelihood of success or failure of our business.
  • Because early-stage drug development requires major capital investment and is subject to various challenges, as we continue to incur operating losses, we will need to raise additional capital or form strategic partnerships to support our research and development activities in the future, which activities may not result in the results desired or further our business.
  • We face significant risks and uncertainties surrounding our Influenza A program following an initial Phase 2a study which failed to yield scientifically viable results relating to the product candidate’s efficacy.
  • RISKS RELATED TO THE DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF PRODUCT CANDIDATES
  • Our programs are in the early clinical stage and we face significant competition from major companies who have developed vaccines or treatments. If we fail to gain market share because our competitors develop and successfully commercialize effective vaccines or therapies or if we fail to obtain or maintain FDA authorization or to otherwise account for uncertainties surrounding the virus, our business and future prospects could be materially and adversely affected.
  • If we form strategic alliances which are unsuccessful or are terminated, we may be unable to develop or commercialize certain product candidates and we may be unable to generate revenues from our development programs.
  • We expect to rely on third parties to conduct some or all aspects of our compound formulation, research and preclinical testing, if those third parties do not perform satisfactorily our business and future prospects would be materially and adversely affected.
The other 44 risks
  • Because we intend to rely on third-party manufacturers to produce our preclinical and clinical supplies, and commercial supplies of any approved product candidates, we will be subject to a variety of risks.
  • Because we expect to rely on limited sources of supply for the drug substance and drug product of product candidates, any disruption in the chain of supply may cause a delay in developing and commercializing these product candidates.
  • If third party manufacturing issues arise, it could increase product and regulatory approval costs or delay commercialization.
  • Since we expect to continue to rely on third parties to conduct, supervise and monitor our clinical trials, if those third parties fail to perform in a satisfactory manner and one that meets applicable regulatory, scientific and safety requirements, it may materially harm our business.
  • Because the approach we are taking to discover and develop drugs is novel, it may never lead to marketable products.
  • If we do not succeed in our efforts to identify or discover additional potential product candidates, your investment may be lost.
  • Because our future commercial success depends on gaining regulatory approval for our products, we cannot generate revenue without obtaining approvals, which is a lengthy and uncertain process.
  • If we are unable to successfully complete preclinical testing and clinical trials of our product candidates or experience significant delays in doing so, our business will be materially harmed.
  • We may be unable to demonstrate safety and efficacy of our product candidates to the satisfaction of regulatory authorities or we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
  • Our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.
  • Following regulatory approval for a product candidate, we will still face extensive regulatory requirements and the approved product may face future development and regulatory difficulties.
  • We may not succeed in obtaining or maintaining necessary rights to drug compounds and processes for our development pipeline through acquisitions and in-licenses.
  • Because third parties may be developing competitive products without our knowledge, we may later learn that competitive products are superior to our product candidates which may force us to terminate our research efforts of one or more product candidates.
  • We have limited experience in conducting and managing the preclinical development activities and clinical trials necessary to obtain approvals for marketing our product candidates, including approval by the FDA.
  • RISKS RELATED TO OUR BUSINESS OPERATIONS AND INDUSTRY
  • If we cannot obtain or protect intellectual property rights related to our future products and product candidates, we may not be able to compete effectively in our markets.
  • If third-party intellectual property infringement claims are asserted against us, it may prevent or delay our development and commercialization efforts and have a material adverse effect on our business and future prospects.
  • We may in the future be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
  • We may need to obtain additional licenses to intellectual property rights from third parties.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
  • Because we face significant competition from other biotechnology and pharmaceutical companies, our operating results will suffer if we fail to compete effectively.
  • Our business could be negatively impacted by cybersecurity threats and other security threats and disruptions.
  • Failure of our information technology infrastructure to operate effectively could adversely affect our business.
  • Artificial intelligence presents risks and challenges that can negatively impact our business.
  • The commercial success of our product candidates will depend upon the acceptance of these product candidates by the medical community, including physicians, patients and healthcare payors.
  • If insurance and/or government coverage and adequate reimbursement are not available for our product candidates, it could impair our ability to achieve and maintain profitability.
  • Due to the 2025 inauguration of a new presidential administration in the U.S., we and our industry face uncertainty including the potential for reduced government funding of research programs and staff and resource reductions at the FDA and other government agencies, which may adversely affect our business.
  • If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenues from product sales.
  • If we obtain approval to commercialize any approved products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.
  • If we lose key management or scientific personnel, cannot recruit qualified employees, directors, officers, or other personnel or experience increases in our compensation costs, our business may materially suffer.
  • If we expand our organization, we may experience difficulties in managing growth, which could disrupt our operations.
  • Any relationships with customers and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
  • Because we face potential product liability if claims are brought against us, we may incur substantial liability and costs.
  • Business interruptions resulting from pandemics, natural disasters and adverse weather events could cause delays in research and development of our product candidates.
  • If our information technology systems are compromised, the information we store and process, including our intellectual property, could be accessed, publicly disclosed, lost or stolen, which could harm our business, relationships with strategic partners and future results of operations.
  • If we fail to comply with applicable laws and regulations, including environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.
  • RISKS RELATED TO OUR COMMON STOCK
  • Our stock price and trading volume has historically been volatile, and any increases in these metrics may be temporary for a number of reasons, which may cause investors to lose money.
  • Due to factors beyond our control, our common stock price may be volatile, or may decline regardless of our operating performance, and you may not be able to resell your shares.
  • Because of central bank actions to combat inflation, the imposition of and uncertainties surrounding tariffs, wars and geopolitical conflicts, and other major events, the effect on the capital markets and the economy is uncertain, and we may have to deal with a recessionary economy and economic uncertainty including possible material adverse effects upon our business.
  • Future issuances of our common stock or rights to purchase our common stock could cause additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
  • Future sales of large amounts of our common stock in the public market or a perception that such sales might occur could cause a decrease in our stock price.
  • Our ability to use our net operating loss carry forwards and certain other tax attributes may be limited.
  • Because we may not attract the attention of major brokerage firms, it could have a material impact upon the price of our common stock.
  • We may issue preferred stock which could make it more difficult for a third-party to acquire us and could depress our stock price.
  • Our amended and restated Bylaws provide for an exclusive forum in the Court of Chancery of the State of Delaware for certain disputes between us and our stockholders, and the exclusive forum in the Delaware federal courts for the resolution of any complaint asserting a cause of action under the Securities Act and the Exchange Act.

Legal proceedings

From time to time, the Company is a party to, or otherwise involved in, legal proceedings arising in the normal course of business. As of the date of this Report, the Company is not aware of any pending legal proceedings to which the Company or any of its subsidiaries is a party which, if determined adversely, would have a material effect on its business, results of operations, cash flows or financial position.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54